Advertisement

Infection

, Volume 40, Issue 6, pp 677–684 | Cite as

Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation

  • A. EgliEmail author
  • C. Bucher
  • A. Dumoulin
  • M. Stern
  • A. Buser
  • L. Bubendorf
  • M. Gregor
  • P. Servida
  • G. Sommer
  • J. Bremerich
  • A. Gratwohl
  • N. Khanna
  • A. F. Widmer
  • M. Battegay
  • M. Tamm
  • H. H. Hirsch
  • J. P. Halter
Brief Report

Abstract

Background

The clinical characteristics of human metapneumovirus (hMPV)-associated lower respiratory tract infection (LRTI) after allogeneic hematopoietic stem cell transplantation (HSCT) is not well described. We describe the clinical course in eight HSCT recipients suffering from hMPV infection.

Methods

We prospectively included all patients with hMPV-associated LRTI after allogeneic HSCT during a period of 1 year. hMPV was diagnosed by multiplex polymerase chain reaction (PCR) from bronchoalveolar lavage (BAL).

Results

Eight patients with hMPV-associated LRTI were identified from 93 BAL samples. Three of the eight patients had co-infections with other pathogens. The median age of the patients was 45 years [interquartile range (IQR) 36.8–53.5], the median time posttransplant was 473 days (IQR 251–1,165), 5/8 patients had chronic graft-versus-host disease (cGvHD), and 6/8 patients received immunosuppression. Chest computed tomography (CT) scanning showed a ground-glass pattern in 7/8 patients. Seven of eight patients required hospitalization due to severe symptoms and hypoxemia. All were treated with intravenous immunoglobulin (IVIG), which was combined with oral ribavirin in six patients. The mortality rate was 12.5 % (1/8).

Conclusions

hMPV-associated LRTI in allogeneic HSCT recipients are not uncommon and present with unspecific respiratory symptoms, ground-glass pattern in CT scanning, and co-infection.

Keywords

Human metapneumovirus Posttransplant infection Treatment Allogeneic hematopoietic stem cell transplantation Respiratory virus 

Notes

Conflict of interest

All authors do not have a conflict of interest.

References

  1. 1.
    Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143:455–67.PubMedGoogle Scholar
  2. 2.
    Anderson EJ. Viral diagnostics and antiviral therapy in hematopoietic stem cell transplantation. Curr Pharm Des. 2008;14:1997–2010.PubMedCrossRefGoogle Scholar
  3. 3.
    Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther. 2007;12:627–38PubMedGoogle Scholar
  4. 4.
    van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7:719–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Chatzidimitriou D, Gavriilaki E, Sakellari I, Diza E. Hematopoietic cell transplantation and emerging viral infections. J Med Virol. 2010;82:528–38.PubMedCrossRefGoogle Scholar
  6. 6.
    Papenburg J, Boivin G. The distinguishing features of human metapneumovirus and respiratory syncytial virus. Rev Med Virol. 2010;20:245–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28:479–84.PubMedCrossRefGoogle Scholar
  8. 8.
    Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008;46:402–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Dumoulin A, Widmer AF, Hirsch HH. Comprehensive diagnostics for respiratory virus infections after transplantation or after potential exposure to swine flu A/H1N1: what else is out there? Transpl Infect Dis. 2009;11:287–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Reijans M, Dingemans G, Klaassen CH, et al. RespiFinder: a new multiparameter test to differentially identify fifteen respiratory viruses. J Clin Microbiol. 2008;46:1232–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Bonney D, Razali H, Turner A, Will A. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol. 2009;145:667–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem. 2006;13:3351–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Campbell AP, Chien JW, Kuypers J, et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis. 2010;201:404–13.CrossRefGoogle Scholar
  14. 14.
    Debur MC, Vidal LR, Stroparo E, et al. Human metapneumovirus infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2010;12:173–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Oliveira R, Machado A, Tateno A, Boas LV, Pannuti C, Machado C. Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years. Bone Marrow Transplant. 2008;42:265–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Cane PA, van den Hoogen BG, Chakrabarti S, Fegan CD, Osterhaus AD. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant. 2003;31:309–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Englund JA, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006;144:344–9.PubMedGoogle Scholar
  18. 18.
    Franquet T, Rodríguez S, Martino R, Salinas T, Giménez A, Hidalgo A.. Human metapneumovirus infection in hematopoietic stem cell transplant recipients: high-resolution computed tomography findings. J Comput Assist Tomogr. 2005;29:223–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Huck B, Egger M, Bertz H, et al. Human metapneumovirus infection in a hematopoietic stem cell transplant recipient with relapsed multiple myeloma and rapidly progressing lung cancer. J Clin Microbiol. 2006;44:2300–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Ison MG, Hayden FG. Viral infections in immunocompromised patients: what’s new with respiratory viruses? Curr Opin Infect Dis. 2002;15:355–67.PubMedCrossRefGoogle Scholar
  21. 21.
    Lacey SF, Diamond DJ, Zaia JA. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant. 2004;10:433–47.PubMedCrossRefGoogle Scholar
  22. 22.
    Safdar A. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplant. 2008;41:707–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Fischer SA. Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation. 2008;86:1327–39.PubMedCrossRefGoogle Scholar
  24. 24.
    Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006;50:774–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • A. Egli
    • 1
    • 2
    Email author
  • C. Bucher
    • 1
  • A. Dumoulin
    • 2
  • M. Stern
    • 1
  • A. Buser
    • 1
    • 3
  • L. Bubendorf
    • 4
  • M. Gregor
    • 5
  • P. Servida
    • 6
  • G. Sommer
    • 7
  • J. Bremerich
    • 7
  • A. Gratwohl
    • 1
  • N. Khanna
    • 8
  • A. F. Widmer
    • 8
  • M. Battegay
    • 8
  • M. Tamm
    • 9
  • H. H. Hirsch
    • 2
    • 8
  • J. P. Halter
    • 1
  1. 1.HematologyUniversity Hospitals of BaselBaselSwitzerland
  2. 2.Transplantation Virology, Department Biomedizin, Institute for Medical MicrobiologyUniversity of BaselBaselSwitzerland
  3. 3.Blood Transfusion Center, Swiss Red CrossUniversity Hospital of BaselBaselSwitzerland
  4. 4.Institute for PathologyUniversity of BaselBaselSwitzerland
  5. 5.Division of HematologyKantonsspital LuzernLuzernSwitzerland
  6. 6.Division of HematologyEOC BellinzonaBellinzonaSwitzerland
  7. 7.Clinic for Radiology and Nuclear MedicineUniversity Hospital of BaselBaselSwitzerland
  8. 8.Infectious Diseases and Hospital EpidemiologyUniversity Hospital of BaselBaselSwitzerland
  9. 9.Clinic of PneumologyUniversity Hospitals of BaselBaselSwitzerland

Personalised recommendations